Arch Therapeutics IncOTCQB:ARTH
- LAST PRICE0.2000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.1500/ 100
- Ask / Lots0.5000/ 40
- Open / Previous Close0.2000 / 0.2000
- Day Range
- 52 Week Range
- Volume2,475
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ARTH |
|---|---|---|
| 09:32 ET | 2000 | 0.2 |
| 12:26 ET | 462 | 0.2 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arch Therapeutics Inc | 888.9K | -0.1x | --- |
Nano Mobile Healthcare Inc | 654.8K | 0.0x | --- |
Tiderock Companies Inc | 1.0M | 0.0x | --- |
Yourspace America Inc | 1.3M | -11.6x | --- |
Citrine Global Corp | 289.7K | -0.1x | --- |
Sunridge International | 4.9K | 0.0x | --- |
Company Information
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.
Contact Information
- Headquarters
- 235 Walnut Street, Suite 6FRAMINGHAM, MA, United States 01702
- Phone
- 617-431-2313
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- Terrence Norchi
- Chief Financial Officer, Treasurer
- Michael Abrams
- Vice President - Sales
- Shawn Carlson
- Independent Director
- Guy Fish
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $888.9K |
|---|---|
Revenue (TTM) | $148.2K |
Shares Outstanding | 4.4M |
Arch Therapeutics Inc does not pay a dividend. | |
Beta | 3.45 |
EPS | $-3.69 |
Book Value | $-1.60 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,186.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
